Franklin Genomic AdvancementHELXETF
13F holders, Q4 2024 (December 31)8holders +3
4new positions
1sold out
1famous investor
$28.85avg. 13F price*
At the end of Q4 2024, 8 institutions reported holding Franklin Genomic Advancement (HELX) in their 13F filings, up 3 from Q3 2024. 4 opened new positions and 1 sold out. The largest holders were Jane Street Group, LLC ($1.2M), Glenview Trust Co ($941K) and LPL Financial LLC ($489K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Franklin Genomic Advancement
- CUSIP
- 35473P520
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $1.5M |
| Exits | 1 | $66 |
All 13F filers, Q3 2024 → Q4 2024: 55,369 shares bought and 2 shares sold, net +55,367 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Jane Street Group, LLC | 0.00% | New | 41,030 | $1.2M |
| Glenview Trust Co | 0.02% | No change | 32,625 | $941K |
| LPL Financial LLC | 0.00% | Add +19.5% | 16,965 | $489K |
| Citadel Advisors | 0.00% | New | 7,966 | $230K |
| UBS Group AG | 0.00% | Add +371.5% | 2,117 | $61K |
| Halbert Hargrove Global Advisors, LLC | 0.00% | New | 1,801 | $52K |
| Royal Bank of Canada | 0.00% | No change | 400 | $12K |
| Harbour Investments, Inc. | 0.00% | New | 136 | $4K |
"% of holder's portfolio" is HELX's weight in each manager's 13F, not the share of Franklin Genomic Advancement the manager owns.